Thalassemia comprises genetic disorders causing imbalanced globin chain production, leading to anemia and iron issues. Current therapies involve lifelong transfusions, posing health challenges. GemPharmatech has created two mouse models: the NCG-X model, which develops spontaneous anemia and supports human HSC erythroid reconstitution, and globin gene knockout mice, which replicate thalassemia symptoms, making them ideal for testing genetic modifications. These models are pivotal for advancing thalassemia treatment research.